- US drugs are expensive, and prices are rising. But executives at 7 top pharmaceutical companies testified at a Congressional hearing today that their companies keep only some of those high price tags, because of discounts and rebates they pay to other industry players.
- The expensive, public “list” prices of US drugs are “actually working against the patient,” Merck CEO Kenneth Frazier said.
- Sanofi CEO Olivier Brandicourt also provided an unusual look behind the curtain of drug prices as part of the hearing, with a chart detailing those rebates.
- The breakdown shows that Sanofi kept less than half of its gross US sales last year. But it also raises additional questions.
US drug prices are high. But pharmaceutical companies insist that isn’t the whole story, including on Tuesday, when seven top executives were grilled by senators on the subject.
As part of the Tuesday hearing, Sanofi CEO Olivier Brandicourt provided a rare look behind the curtain of drug prices, with a detailed breakdown of the company’s US sales last year.
Drugmakers have been increasingly vocal that a drug’s list price doesn’t reflect the discounts and rebates that they pay to other healthcare industry players, like private insurers, pharmacy-benefit managers, and government programs.
The result, they say, is that the money they take home (also called the “net” price) is significantly lower.
“The list price is actually working against the patient,” Merck CEO Kenneth Frazier said, referring to the expensive, public “list” price of US drugs. New Jersey-based Merck has a $US210-billion market value, and the cancer drug Keytruda and HPV vaccine Gardasil are among its most profitable products.
To demonstrate that argument, Sanofi’s Brandicourt released a chart showing Sanofi and its Genzyme unit’s US sales from last year. It displays how much of the company’s sales went to discounts and rebates, and was included in the company’s prepared testimony.
Sanofi is based in Paris, France and has a roughly $US52 billion market value. The company is perhaps best known for its long-acting insulin brand Lantus, which is the world’s top-selling diabetes medication.
The chart shows that of Sanofi’s $US21.6 billion in gross sales in 2018, it kept less than half the revenue, or about $US8.4 billion.
That’s still a tremendous figure, of course. And the chart raises additional questions. Importantly, the chart doesn’t illustrate how drug companies themselves benefit from rebates.
Take Sanofi, which paid $US7.3 billion in “discretionary” rebates last year, to commercial health insurance plans and others.
Drug companies use those rebates as a negotiating tactic to get health insurers to cover their medications.
In other words: If Sanofi had agreed to pay fewer rebates last year, it’s possible that the company’s gross sales figure might have been smaller.
Moreover, the Trump administration is proposing getting rid of rebates, at least in some government programs. The pharmaceutical industry has applauded that proposal.
Yet critics have pointed out that the Trump administration proposal doesn’t require drug companies to lower their prices.
Asked whether a change to the rebate system would lead them to lower list prices, some of the seven executives present at the hearing said yes, unequivocally.
Pfizer CEO Albert Bourla said “we will not keep a single dollar,” and called for the change to be extended to commercial health-insurance plans.
Jennifer Taubert, an executive at Johnson & Johnson’s Janssen pharmaceutical unit, said that the company was “supportive” but would need to see the final change and make sure additional fees weren’t added to the system to compensate.
Never miss out on healthcare news. Subscribe to Dispensed, our weekly newsletter on pharma, biotech, and healthcare.
One CEO, AstraZeneca’s Pascal Soriot, said in his opening statement on Tuesday – even before the question was asked – that his company was “prepared to reduce our list prices” by around the level it pays it rebates.
He also suggested that for seniors covered by the government’s Medicare program, a portion of discounts and rebates could help cap their out-of-pocket costs, so they could have more predictable costs. That model has been used successfully in other countries, Soriot said.
Business Insider Emails & Alerts
Site highlights each day to your inbox.